ALLO
Price
$1.95
Change
+$0.05 (+2.63%)
Updated
Jun 17, 04:59 PM (EDT)
Capitalization
676.5M
49 days until earnings call
Intraday BUY SELL Signals
NKTX
Price
$2.64
Change
+$0.02 (+0.76%)
Updated
Jun 17, 04:59 PM (EDT)
Capitalization
187.09M
50 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALLO vs NKTX

Header iconALLO vs NKTX Comparison
Open Charts ALLO vs NKTXBanner chart's image
ALLO vs NKTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALLO vs. NKTX commentary
Jun 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and NKTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 18, 2026
Stock price -- (ALLO: $1.91 vs. NKTX: $2.62)
Brand notoriety: ALLO and NKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 43% vs. NKTX: 42%
Market capitalization -- ALLO: $676.5M vs. NKTX: $188.88M
ALLO [@Biotechnology] is valued at $676.5M. NKTX’s [@Biotechnology] market capitalization is $188.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $116.49B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileNKTX’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • NKTX’s FA Score: 1 green, 4 red.
According to our system of comparison, NKTX is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 4 TA indicator(s) are bullish while NKTX’s TA Score has 3 bullish TA indicator(s).

  • ALLO’s TA Score: 4 bullish, 4 bearish.
  • NKTX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than NKTX.

Price Growth

ALLO (@Biotechnology) experienced а +4.95% price change this week, while NKTX (@Biotechnology) price change was +6.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.03%. For the same industry, the average monthly price growth was +6.58%, and the average quarterly price growth was +2216.76%.

Reported Earning Dates

ALLO is expected to report earnings on Aug 05, 2026.

NKTX is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (+4.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($677M) has a higher market cap than NKTX($187M). NKTX (41.351) and ALLO (39.416) have similar YTD gains . NKTX has higher annual earnings (EBITDA): -107.08M vs. ALLO (-160.41M). ALLO has more cash in the bank: 267M vs. NKTX (230M). ALLO (72.6M) and NKTX (75M) have identical debt. ALLO (0) and NKTX (0) have equivalent revenues.
ALLONKTXALLO / NKTX
Capitalization677M187M362%
EBITDA-160.41M-107.08M150%
Gain YTD39.41641.35195%
P/E RatioN/AN/A-
Revenue00-
Total Cash267M230M116%
Total Debt72.6M75M97%
FUNDAMENTALS RATINGS
ALLO vs NKTX: Fundamental Ratings
ALLO
NKTX
OUTLOOK RATING
1..100
5987
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
4841
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a23

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NKTX's Valuation (8) in the null industry is significantly better than the same rating for ALLO (94) in the Biotechnology industry. This means that NKTX’s stock grew significantly faster than ALLO’s over the last 12 months.

NKTX's Profit vs Risk Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that NKTX’s stock grew similarly to ALLO’s over the last 12 months.

NKTX's SMR Rating (98) in the null industry is in the same range as ALLO (99) in the Biotechnology industry. This means that NKTX’s stock grew similarly to ALLO’s over the last 12 months.

NKTX's Price Growth Rating (41) in the null industry is in the same range as ALLO (48) in the Biotechnology industry. This means that NKTX’s stock grew similarly to ALLO’s over the last 12 months.

NKTX's P/E Growth Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that NKTX’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLONKTX
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signal:
Gain/Loss:
NKTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GRSRX59.870.06
+0.10%
Cohen & Steers Global Realty R
MWOKX63.25N/A
N/A
MFS Global Growth R6
MOSAX8.79N/A
N/A
MassMutual Overseas A
VVOCX25.25N/A
N/A
Invesco Value Opportunities C
PVFIX17.60N/A
N/A
Pinnacle Value

NKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with FATE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
-4.56%
FATE - NKTX
50%
Loosely correlated
-5.97%
RXRX - NKTX
50%
Loosely correlated
-3.04%
EDIT - NKTX
50%
Loosely correlated
-4.27%
RCKT - NKTX
49%
Loosely correlated
-2.10%
BEAM - NKTX
47%
Loosely correlated
-0.37%
More